Research ExplorerPublicationsTranscatheter Tricuspid Valve Intervention in Patients With ...

Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry

Standard

Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry. / Muntané-Carol, Guillem; Taramasso, Maurizio; Miura, Mizuki; Gavazzoni, Mara; Pozzoli, Alberto; Alessandrini, Hannes; Latib, Azeem; Attinger-Toller, Adrian; Biasco, Luigi; Braun, Daniel; Brochet, Eric; Connelly, Kim A; de Bruijn, Sabine; Denti, Paolo; Deuschl, Florian; Lubos, Edith; Ludwig, Sebastian; Kalbacher, Daniel; Estevez-Loureiro, Rodrigo; Fam, Neil; Frerker, Christian; Ho, Edwin; Juliard, Jean-Michel; Kaple, Ryan; Kodali, Susheel; Kreidel, Felix; Harr, Claudia; Lauten, Alexander; Lurz, Julia; Monivas, Vanessa; Mehr, Michael; Nazif, Tamin; Nickening, Georg; Pedrazzini, Giovanni; Philippon, François; Praz, Fabien; Puri, Rishi; Schäfer, Ulrich; Schofer, Joachim; Sievert, Horst; Tang, Gilbert H L; Khattab, Ahmed A; Andreas, Martin; Russo, Marco; Thiele, Holger; Unterhuber, Matthias; Himbert, Dominique; Urena, Marina; von Bardeleben, Ralph Stephan; Webb, John G; Weber, Marcel; Windecker, Stephan; Winkel, Mirjam; Zuber, Michel; Hausleiter, Jörg; Lurz, Philipp; Maisano, Francesco; Leon, Martin B; Hahn, Rebecca T; Rodés-Cabau, Josep; TriValve Registry.

In: CIRC-CARDIOVASC INTE, Vol. 14, No. 2, e009685, 02.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Muntané-Carol, G, Taramasso, M, Miura, M, Gavazzoni, M, Pozzoli, A, Alessandrini, H, Latib, A, Attinger-Toller, A, Biasco, L, Braun, D, Brochet, E, Connelly, KA, de Bruijn, S, Denti, P, Deuschl, F, Lubos, E, Ludwig, S, Kalbacher, D, Estevez-Loureiro, R, Fam, N, Frerker, C, Ho, E, Juliard, J-M, Kaple, R, Kodali, S, Kreidel, F, Harr, C, Lauten, A, Lurz, J, Monivas, V, Mehr, M, Nazif, T, Nickening, G, Pedrazzini, G, Philippon, F, Praz, F, Puri, R, Schäfer, U, Schofer, J, Sievert, H, Tang, GHL, Khattab, AA, Andreas, M, Russo, M, Thiele, H, Unterhuber, M, Himbert, D, Urena, M, von Bardeleben, RS, Webb, JG, Weber, M, Windecker, S, Winkel, M, Zuber, M, Hausleiter, J, Lurz, P, Maisano, F, Leon, MB, Hahn, RT, Rodés-Cabau, J & TriValve Registry 2021, 'Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry', CIRC-CARDIOVASC INTE, vol. 14, no. 2, e009685. https://doi.org/10.1161/CIRCINTERVENTIONS.120.009685

APA

Muntané-Carol, G., Taramasso, M., Miura, M., Gavazzoni, M., Pozzoli, A., Alessandrini, H., Latib, A., Attinger-Toller, A., Biasco, L., Braun, D., Brochet, E., Connelly, K. A., de Bruijn, S., Denti, P., Deuschl, F., Lubos, E., Ludwig, S., Kalbacher, D., Estevez-Loureiro, R., ... TriValve Registry (2021). Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry. CIRC-CARDIOVASC INTE, 14(2), [e009685]. https://doi.org/10.1161/CIRCINTERVENTIONS.120.009685

Vancouver

Muntané-Carol G, Taramasso M, Miura M, Gavazzoni M, Pozzoli A, Alessandrini H et al. Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry. CIRC-CARDIOVASC INTE. 2021 Feb;14(2). e009685. https://doi.org/10.1161/CIRCINTERVENTIONS.120.009685

Bibtex

@article{4a5244af8ef444deb3643aaadf3b2c59,
title = "Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry",
abstract = "BACKGROUND: Scarce data exist on patients with right ventricular dysfunction (RVD) or pulmonary hypertension (PH) undergoing transcatheter tricuspid valve intervention. This study aimed to determine the early and midterm outcomes and the factors associated with mortality in this group of patients.METHODS: This subanalysis of the multicenter TriValve (Transcatheter Tricuspid Valve Therapies) registry included 300 patients with severe tricuspid regurgitation with RVD (n=244), PH (n=127), or both (n=71) undergoing transcatheter tricuspid valve intervention. RVD was defined as a tricuspid annular plane systolic excursion <17 mm, and PH as an estimated pulmonary artery systolic pressure ≥50 mm Hg.RESULTS: Mean age of the patients was 77±9 years (54% women). Procedural success was 80.7%, and 9 patients (3%) died during the hospitalization. At a median follow-up of 6 (interquartile range, 2-12) months, 54 patients (18%) died, and the independent associated factors were higher gamma-glutamyl transferase values at baseline (hazard ratio, 1.02 for each increase of 10 u/L [95% CI, 1.002-1.04]), poorer renal function defined as an estimated glomerular filtration rate <45 mL/min (hazard ratio, 2.3 [95% CI, 1.22-4.33]), and the lack of procedural success (hazard ratio, 2.11 [95% CI, 1.17-3.81]). The grade of RVD and the amount of PH at baseline were not found to be predictors of mortality. Most patients alive at follow-up improved their functional class (New York Heart Association I-II in 66% versus 7% at baseline, P<0.001).CONCLUSIONS: In patients with severe tricuspid regurgitation and RVD/PH, transcatheter tricuspid valve intervention was associated with high procedural success and a relatively low in-hospital mortality, along with significant improvements in functional status. However, about 1 out of 5 patients died after a median follow-up of 6 months, with hepatic congestion, renal dysfunction, and the lack of procedural success determining an increased risk. These results may improve the clinical evaluation of transcatheter tricuspid valve intervention candidates and would suggest a closer follow-up in those at increased risk. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03416166.",
author = "Guillem Muntan{\'e}-Carol and Maurizio Taramasso and Mizuki Miura and Mara Gavazzoni and Alberto Pozzoli and Hannes Alessandrini and Azeem Latib and Adrian Attinger-Toller and Luigi Biasco and Daniel Braun and Eric Brochet and Connelly, {Kim A} and {de Bruijn}, Sabine and Paolo Denti and Florian Deuschl and Edith Lubos and Sebastian Ludwig and Daniel Kalbacher and Rodrigo Estevez-Loureiro and Neil Fam and Christian Frerker and Edwin Ho and Jean-Michel Juliard and Ryan Kaple and Susheel Kodali and Felix Kreidel and Claudia Harr and Alexander Lauten and Julia Lurz and Vanessa Monivas and Michael Mehr and Tamin Nazif and Georg Nickening and Giovanni Pedrazzini and Fran{\c c}ois Philippon and Fabien Praz and Rishi Puri and Ulrich Sch{\"a}fer and Joachim Schofer and Horst Sievert and Tang, {Gilbert H L} and Khattab, {Ahmed A} and Martin Andreas and Marco Russo and Holger Thiele and Matthias Unterhuber and Dominique Himbert and Marina Urena and {von Bardeleben}, {Ralph Stephan} and Webb, {John G} and Marcel Weber and Stephan Windecker and Mirjam Winkel and Michel Zuber and J{\"o}rg Hausleiter and Philipp Lurz and Francesco Maisano and Leon, {Martin B} and Hahn, {Rebecca T} and Josep Rod{\'e}s-Cabau and {TriValve Registry}",
year = "2021",
month = feb,
doi = "10.1161/CIRCINTERVENTIONS.120.009685",
language = "English",
volume = "14",
journal = "CIRC-CARDIOVASC INTE",
issn = "1941-7640",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry

AU - Muntané-Carol, Guillem

AU - Taramasso, Maurizio

AU - Miura, Mizuki

AU - Gavazzoni, Mara

AU - Pozzoli, Alberto

AU - Alessandrini, Hannes

AU - Latib, Azeem

AU - Attinger-Toller, Adrian

AU - Biasco, Luigi

AU - Braun, Daniel

AU - Brochet, Eric

AU - Connelly, Kim A

AU - de Bruijn, Sabine

AU - Denti, Paolo

AU - Deuschl, Florian

AU - Lubos, Edith

AU - Ludwig, Sebastian

AU - Kalbacher, Daniel

AU - Estevez-Loureiro, Rodrigo

AU - Fam, Neil

AU - Frerker, Christian

AU - Ho, Edwin

AU - Juliard, Jean-Michel

AU - Kaple, Ryan

AU - Kodali, Susheel

AU - Kreidel, Felix

AU - Harr, Claudia

AU - Lauten, Alexander

AU - Lurz, Julia

AU - Monivas, Vanessa

AU - Mehr, Michael

AU - Nazif, Tamin

AU - Nickening, Georg

AU - Pedrazzini, Giovanni

AU - Philippon, François

AU - Praz, Fabien

AU - Puri, Rishi

AU - Schäfer, Ulrich

AU - Schofer, Joachim

AU - Sievert, Horst

AU - Tang, Gilbert H L

AU - Khattab, Ahmed A

AU - Andreas, Martin

AU - Russo, Marco

AU - Thiele, Holger

AU - Unterhuber, Matthias

AU - Himbert, Dominique

AU - Urena, Marina

AU - von Bardeleben, Ralph Stephan

AU - Webb, John G

AU - Weber, Marcel

AU - Windecker, Stephan

AU - Winkel, Mirjam

AU - Zuber, Michel

AU - Hausleiter, Jörg

AU - Lurz, Philipp

AU - Maisano, Francesco

AU - Leon, Martin B

AU - Hahn, Rebecca T

AU - Rodés-Cabau, Josep

AU - TriValve Registry

PY - 2021/2

Y1 - 2021/2

N2 - BACKGROUND: Scarce data exist on patients with right ventricular dysfunction (RVD) or pulmonary hypertension (PH) undergoing transcatheter tricuspid valve intervention. This study aimed to determine the early and midterm outcomes and the factors associated with mortality in this group of patients.METHODS: This subanalysis of the multicenter TriValve (Transcatheter Tricuspid Valve Therapies) registry included 300 patients with severe tricuspid regurgitation with RVD (n=244), PH (n=127), or both (n=71) undergoing transcatheter tricuspid valve intervention. RVD was defined as a tricuspid annular plane systolic excursion <17 mm, and PH as an estimated pulmonary artery systolic pressure ≥50 mm Hg.RESULTS: Mean age of the patients was 77±9 years (54% women). Procedural success was 80.7%, and 9 patients (3%) died during the hospitalization. At a median follow-up of 6 (interquartile range, 2-12) months, 54 patients (18%) died, and the independent associated factors were higher gamma-glutamyl transferase values at baseline (hazard ratio, 1.02 for each increase of 10 u/L [95% CI, 1.002-1.04]), poorer renal function defined as an estimated glomerular filtration rate <45 mL/min (hazard ratio, 2.3 [95% CI, 1.22-4.33]), and the lack of procedural success (hazard ratio, 2.11 [95% CI, 1.17-3.81]). The grade of RVD and the amount of PH at baseline were not found to be predictors of mortality. Most patients alive at follow-up improved their functional class (New York Heart Association I-II in 66% versus 7% at baseline, P<0.001).CONCLUSIONS: In patients with severe tricuspid regurgitation and RVD/PH, transcatheter tricuspid valve intervention was associated with high procedural success and a relatively low in-hospital mortality, along with significant improvements in functional status. However, about 1 out of 5 patients died after a median follow-up of 6 months, with hepatic congestion, renal dysfunction, and the lack of procedural success determining an increased risk. These results may improve the clinical evaluation of transcatheter tricuspid valve intervention candidates and would suggest a closer follow-up in those at increased risk. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03416166.

AB - BACKGROUND: Scarce data exist on patients with right ventricular dysfunction (RVD) or pulmonary hypertension (PH) undergoing transcatheter tricuspid valve intervention. This study aimed to determine the early and midterm outcomes and the factors associated with mortality in this group of patients.METHODS: This subanalysis of the multicenter TriValve (Transcatheter Tricuspid Valve Therapies) registry included 300 patients with severe tricuspid regurgitation with RVD (n=244), PH (n=127), or both (n=71) undergoing transcatheter tricuspid valve intervention. RVD was defined as a tricuspid annular plane systolic excursion <17 mm, and PH as an estimated pulmonary artery systolic pressure ≥50 mm Hg.RESULTS: Mean age of the patients was 77±9 years (54% women). Procedural success was 80.7%, and 9 patients (3%) died during the hospitalization. At a median follow-up of 6 (interquartile range, 2-12) months, 54 patients (18%) died, and the independent associated factors were higher gamma-glutamyl transferase values at baseline (hazard ratio, 1.02 for each increase of 10 u/L [95% CI, 1.002-1.04]), poorer renal function defined as an estimated glomerular filtration rate <45 mL/min (hazard ratio, 2.3 [95% CI, 1.22-4.33]), and the lack of procedural success (hazard ratio, 2.11 [95% CI, 1.17-3.81]). The grade of RVD and the amount of PH at baseline were not found to be predictors of mortality. Most patients alive at follow-up improved their functional class (New York Heart Association I-II in 66% versus 7% at baseline, P<0.001).CONCLUSIONS: In patients with severe tricuspid regurgitation and RVD/PH, transcatheter tricuspid valve intervention was associated with high procedural success and a relatively low in-hospital mortality, along with significant improvements in functional status. However, about 1 out of 5 patients died after a median follow-up of 6 months, with hepatic congestion, renal dysfunction, and the lack of procedural success determining an increased risk. These results may improve the clinical evaluation of transcatheter tricuspid valve intervention candidates and would suggest a closer follow-up in those at increased risk. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03416166.

U2 - 10.1161/CIRCINTERVENTIONS.120.009685

DO - 10.1161/CIRCINTERVENTIONS.120.009685

M3 - SCORING: Journal article

C2 - 33541097

VL - 14

JO - CIRC-CARDIOVASC INTE

JF - CIRC-CARDIOVASC INTE

SN - 1941-7640

IS - 2

M1 - e009685

ER -